Companies › Omikron Italia S.r.l.
1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Citicoline eye drops 2% Phosphatidylcholine precursor with neuroprotective properties | PCYT1A | Phase 3 | Glaucoma, Open-Angle | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05710198 | Citicoline eye drops 2% | Phase 3 | Glaucoma, Open-Angle | Ophthalmology | Apr 2027 |
–
Cloudbreak Therapeutics Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.